Galyan, Simon Marius
Ewald, Collin Y.
Jalencas, Xavier
Masrani, Shyam
Meral, Selin
Mestres, Jordi
Funding for this research was provided by:
EIT Health (2017 HS PoC GER03)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF P3 Project 190072)
Article History
Received: 19 May 2022
Accepted: 5 October 2022
First Online: 16 November 2022
Competing interests
: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. SME is the Chief Executive Officer (CEO) of Galyan Bio, Inc. CYE is a professor at ETH Zurich but also a co-founder and shareholder of Avea Life AG, and is on the Scientific Advisory Board of Maximon AG and Galyan Bio, Inc. KL is Managing Director of Bicoll GmbH and Director and General Manager of Bicoll Biotechnology (Shanghai) Co. Ltd. All other authors do not have any conflicts of interest to declare.